{"entity":{"id":"precise-mrd","kind":"drug","name":"Precise MRD","aka":["Myriad Precise MRD"],"tldr":"Myriad Genetics' whole-genome blood test for leftover cancer, launched in 2026 for breast cancer and extended to bowel and kidney cancer.","summary":"Myriad Genetics launched Precise MRD on 2 March 2026 with a select number of oncology practices for patients with breast cancer, describing whole-genome sequencing of the tumour to build a personalised assay with detection of ctDNA down to one part per million. On 23 June 2026 it broadened availability to patients being treated or followed for breast, colorectal and renal cancer, stating that the panel holds up to 1,000 patient-specific variants, and announced publication of the MONITOR-Breast study of ctDNA during neoadjuvant therapy in Future Oncology.","status":"emerging","asOf":"2026-11-03","links":[{"label":"Myriad Genetics launches Precise MRD (2 March 2026)","url":"https://investor.myriad.com/news-releases/news-release-detail/27031/"},{"label":"Myriad Genetics expands Precise MRD to colorectal and renal cancer (23 June 2026)","url":"https://investor.myriad.com/news-releases/news-release-detail/27436/"},{"label":"Myriad Genetics: Precise MRD","url":"https://myriad.com/oncology/precise-mrd-test/"},{"label":"MONITOR-Breast: whole-genome ctDNA dynamics during neoadjuvant therapy (Future Oncology 2026)","url":"https://doi.org/10.1080/14796694.2026.2690165"}],"tags":["test"],"related":["next-personal","signatera"],"cancers":["breast-cancer"],"sections":[],"technologies":["mrd-testing","liquid-biopsy","wes-wgs"],"targets":[],"drugs":[],"companies":["myriad-genetics"],"institutions":[],"pathways":[],"terms":["mrd","ctdna","tumour-informed-assay"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-monitor-breast-foldi-future-oncol-2026"],"journals":[],"dependsOn":[],"notes":["What a result means: the same as other tumour-informed MRD tests; ask whether a positive result would change your treatment before having it.","Not confirmed: Medicare coverage (neither release mentions it and the MolDX billing article A58376 does not list the test) and any FDA designation. Myriad's product page refused automated reading on 3 November 2026, so the press releases are linked."],"brand":"Precise MRD","modality":"Tumour-informed whole-genome ctDNA minimal residual disease test (up to 1,000 variants)","mechanism":"Whole-genome sequencing of tumour tissue builds a panel of up to 1,000 patient-specific variants that is tracked in plasma, with stated detection down to one part per million.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/precise-mrd/","neighbours":{"drug":[{"id":"next-personal","kind":"drug","name":"NeXT Personal Dx","route":"/drugs/next-personal/"},{"id":"signatera","kind":"drug","name":"Signatera","route":"/drugs/signatera/"}],"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"},{"id":"wes-wgs","kind":"technology","name":"Whole-exome & whole-genome sequencing","route":"/technologies/wes-wgs/"}],"company":[{"id":"myriad-genetics","kind":"company","name":"Myriad Genetics","route":"/companies/myriad-genetics/"}],"term":[{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"},{"id":"tumour-informed-assay","kind":"term","name":"Tumour-informed versus tumour-naive ctDNA assays","route":"/terms/tumour-informed-assay/"}],"paper":[{"id":"paper-monitor-breast-foldi-future-oncol-2026","kind":"paper","name":"MONITOR-Breast: whole-genome ctDNA dynamics during neoadjuvant therapy across breast cancer subtypes","route":"/key-papers/paper-monitor-breast-foldi-future-oncol-2026/"}],"roadmap":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/"},{"id":"diagnostics-roadmap","kind":"roadmap","name":"Diagnostics roadmap: stains → gene panels → blood tests that decide treatment","route":"/roadmaps/diagnostics-roadmap/"}],"biomarker":[{"id":"ctdna-mrd-positive","kind":"biomarker","name":"ctDNA MRD positivity (molecular residual disease after curative treatment)","route":"/biomarkers/ctdna-mrd-positive/"}]}}